ASH 2025 | CARTITUDE-4: Long-term PFS outcomes with cilta-cel for standard-risk RRMM
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Multiple Myeloma Hub was pleased to speak with Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked about the long-term PFS outcomes with ciltacabtagene autoleucel (cilta-cel) for standard-risk relapsed/refractory multiple myeloma (RRMM) from the CARTITUDE-4 trial.
In this interview, Costa first provided an overview of the phase III CARTITUDE-4 (NCT04181827) study design, explaining how the findings have impacted the treatment landscape for multiple…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.